Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): A systematic literature review

Value in Health

Volumn 16, Issue 5, 2013, Pages 872-890

  Seal, Brian S ^a   Asche, Carl V ^b   Puto, Katarzyna ^c   Allen, Pamela D ^c  

^a Bayer HealthCare Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c XCENDA   (United States)

Author keywords

bone metastases; castration resistant prostate cancer; chemotherapy; hormonal therapy; overall survival; patient reported outcomes; prostate cancer; radiopharmaceuticals; skeletal related events

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; CANCER VACCINE; CUSTIRSEN; DENOSUMAB; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; GOSERELIN; LENALIDOMIDE; MINERALOCORTICOID; MITOXANTRONE; NILUTAMIDE; ORTERONEL; PREDNISONE; RADIUM CHLORIDE RA 223; SAMARIUM; SAMARIUM 153; SATRAPLATIN; SIPULEUCEL T; TASQUINIMOD; TRIPTORELIN; UNINDEXED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ALOPECIA; ALPHA RADIATION; ANEMIA; ANOREXIA; ARM PAIN; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; BONE PAIN; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; HEART DISEASE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; INFECTION; JAW OSTEONECROSIS; LEG PAIN; LEUKOPENIA; LIVER FUNCTION; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE CANCER; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING; WEAKNESS;

BONE METASTASES; CASTRATION-RESISTANT PROSTATE CANCER; CHEMOTHERAPY; HORMONAL THERAPY; OVERALL SURVIVAL; PATIENT-REPORTED OUTCOMES; PROSTATE CANCER; RADIOPHARMACEUTICALS; SKELETAL-RELATED EVENTS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CANCER VACCINES; DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; SURVIVAL ANALYSIS; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 84881669162     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.03.1628     Document Type: Article

References (78)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. Howlader N, Noone AM, Krapcho M, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute, 2011. Available from: http://seer.cancer.gov/csr/1975-2008/ based on November 2010 SEER data submission, posted to the SEER Web site, 2011 [Accessed March 11, 2013].
3. D. Goetz New options for the management of castration-resistant prostate: a case perspective J Natl Compr Canc Netw 9 Suppl 3 2011 S13 S24
4. S. Goktas, and D. Crawford Optimal hormone therapy for advanced prostatic carcinoma Semin Oncol 26 1999 162 173
5. National Comprehensive Cancer Network (NCCN) Practice Guidelines in OncologyTM. Available from: http://www.nccn.org. [Accessed April 7, 2012].
6. D. George, and J.W. Moul Emerging treatment options for patients with castration-resistant prostate cancer Prostate 72 2012 338 349
7. M.A. Eisenberger, B.A. Blumenstein, and E.D. Crawford Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 339 1998 1036 1042
8. E.D. Crawford, M.A. Eisenberger, and D.G. McLeod A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321 1989 419 424
9. C.S. Higano, and E.D. Crawford New and emerging agents for the treatment of castration-resistant prostate cancer Urol Oncol 29 Suppl 6 2011 S1 S8
10. K.N. Chi, A. Bjartell, and D. Dearnaley Castration-resistant prostate cancer: from new pathophysiology to new treatment targets Eur Urol 56 2009 594 605
11. M. Shelley, C. Harrison, and B. Coles Chemotherapy for hormone-refractory prostate cancer Cochrane Database Syst Rev 18 4 2006 CD 005247
12. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advance refractory prostate cancer N Engl J Med 351 2004 1513 1520
13. IF Tannock, R de Wit, and WR Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
14. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CPRC) patients with bone metastases (ALSYMPCA). Presented at: American Society of Clinical Oncology (ASCO). Chicago, IL, May 31-June 4, 2012.
15. de Bono JS, Fizazi K, Saad F, et al. Phase 3 trial (AFFIRM) of enzalutamide (MDV3100), an androgen receptor signaling inhibitor: primary, secondary, and quality-of-life endpoint results. Presented at: American Society of Clinical Oncology (ASCO). Chicago, IL, May 31-June 4, 2012.
16. S. Nilsson, L. Franzen, and C. Parker Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 7 2007 587 594
17. K.P. Fizazi, J. Beuzeboc, and V. Lumbroso Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer J Clin Oncol 27 15 2009 2429 2435
18. J. Lipscomb, C.C. Gotay, and C.E. Snyder Patient-reported outcomes in cancer: a review of recent research and policy initiatives CA Cancer J Clin 57 2007 278 300
19. N. Mottet, J. Bellmunt, and M. Bolla EUA guidelines on prostate cancer, part II: treatment of advance, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
20. G. Di Lorenzo, C. Buonerba, and R. Autorino Castration-resistant prostate cancer: current and emerging treatment strategies Drugs 70 2010 983 1000
21. R. So-Rosillo, and E.J. Small Sipuleucel-T (APC8015) for prostate cancer Expert Rev Anticancer Ther 9 2006 1163 1167
22. Provenge® (sipuleucel-T) [package insert]. Seattle, WA: Dendreon Corporation, June 2011.
23. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
24. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 19 2006 3089 3094
25. J.G. Mezynski, A. Attard, and D. Zivi Evaluating the antitumour activity of docetaxel following treatment with abiraterone acetate and steroids: evidence for cross-resistance Crit Rev Oncol Hematol 78 Suppl 2011 S23 S24
26. Bompas E, Italiano A, Ortholan C, et al. Docetaxel-based chemotherapy in elderly patients (≥75 years) with castration resistant prostate cancer (CRPC): a French national study of 175 patients. Abstract presented at: ASCO Annual Meeting. Chicago, IL, May 30-June 3, 2008.
27. S. Oudard, E. Banu, and J. Medioni What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int 103 2009 1641 1646
28. D.R. Berthold, G.R. Pond, and M. Roessner Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study Clin Cancer Res 14 2008 2763 2767
29. D.R. Berthold, G.R. Pond, and R. de Wit Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann Oncol 19 2008 1749 1753
30. Saad F, Perez J, Cook R, et al. Evaluation of prostate-specific antigen kinetics during zoledronic acid therapy for bone metastases in patients with castration-resistant prostate cancer. Abstract presented at: AUA Annual Meeting. Washington, DC, May 14-19, 2011.
31. Nilsson S, Parker C, Biggin C, et al. Clinical experience and radiation safety of the first-in-class alpha-pharmaceutical, Alpharadin™ (radium-223), in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Poster presented at: American Society for Radiation Oncology (ASTRO). San Diego, CA, October 21-November 4, 2010.
32. M.D. Michaelson, D.S. Kaufman, P. Kantoff, and M.R. Smith Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer Cancer 107 2006 530 535
33. K.N. Chi, S.J. Hotte, and E.Y. Yu Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 4247 4254
34. Parker C, O'Bryan-Tear CG, Bolstad B, et al. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. Poster presented at: American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. San Francisco, CA, March 5-7, 2010.
35. C.N. Sternberg, D.P. Petrylak, and O. Sartor Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 32 2009 5431 5438
36. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. Abstract presented at: ASCO Annual Meeting. Chicago, IL, June 4-8, 2010.
37. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial Lancet 376 2010 1147 1154
38. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
39. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
40. Meulenbeld HJ, van Werkhoven ED, Coenen JLLM, et al. Randomized phase III study of docetaxel with or without risedronate in patients with bone metastases from castration-resistant prostate cancer (CRPC): the Netherlands Prostate Study (NePro). Abstract presented at: ASCO Annual Meeting. Chicago, IL, June 3-7, 2011.
41. B. Tombal, S. Oudard, and M. Ozguroglu Clinical benefit of cabazitaxel plus prednisone in the TROPIC trial in men with metastatic castration resistant prostate cancer (mCRPC) who progressed after docetaxel-based treatment Eur Urol Suppl 10 2011 335 336
42. Sternberg CN, Scher HI, Molina A, et al. Fatigue improvement/reduction with abiraterone acetate in patients with metastatic castration-resistant prostate cancer post-docetaxel: results from the COU-AA-301 phase 3 study. Poster presented at: European Multidisciplinary Cancer Congress (EMCC). Stockholm, Sweden, September 23-27, 2011.
43. E.M. Basch, J.S. de Bono, and H.I. Scher Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCPRC) treated with abiraterone acetate (AA): long-term follow-up J Clin Oncol Suppl. 5 2012 abstract 183
44. Ryan CJ, de Bono JS, Molina A, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase 3 study of abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presentation presented at: American Society of Clinical Oncology (ASCO). Chicago, IL, May 31-June 4, 2012.
45. A.O. Sartor, D. Heinrich, and J.M. O'Sullivan Radium-223 chloride (Ra-223) impact on skeletal related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA) J Clin Oncol Suppl 2012 abstract 4551
46. L. Moser, T. Schubert, and W. Hinkelbein Hormone-refractory and metastatic prostate cancer - palliative radiotherapy Front Radiat Ther Oncol 41 2008 117 125
47. K. Liepe Alpharadin, a 223Ra-based (alpha)-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer Curr Opin Investig Drugs 12 10 2009 1346 1358
48. P. Vogiatzi, M. Cassone, and L. Claudio Targeted therapy for advanced prostate cancer: looking through new lenses Drug News Perspect 22 2009 593 601
49. G. Colloca, A. Venturino, and F. Checcaglini Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review Cancer Treat Rev 36 2010 501 506
50. R.J. Lee, P.J. Saylor, and M.R. Smith Contemporary therapeutic approaches targeting bone complications in prostate cancer Clin Genitourin Cancer 8 2010 29 36
51. M. Mason, N. Freemantle, and A. Parnaby No conclusive evidence from randomized controlled trials (RCTs) for improved survival with second-line treatment options, in patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with docetaxel Value Health 13 2010 A254
52. D. Santini, S. Galluzzo, and A. Zoccoli New molecular targets in bone metastases Cancer Treat Rev 36 Suppl. 3 2010 S6 10
53. D.J. Bourgeois, S. Kraus, and B.N. Maaloof Radiation for bone metastases Curr Opin Support Palliat Care 5 2011 227 232
54. T.A. Yap, A. Zivi, and A. Omlin The changing therapeutic landscape of castration-resistant prostate cancer Nat Rev Clin Oncol 8 2011 597 610
55. G. Attard, A.S. Belldegrun, and J.S. de Bono Selective blockage of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer BJU Int 96 2005 1241 1246
56. D. Osoba, I.F. Tannock, and D.S. Ernst Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone J Clin Oncol 17 1999 1654 1663
57. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
58. ® (docetaxel) [package insert]. Bridgewater, NJ: Sanofi-Aventis, U.S. LLC, May 2010.
59. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
60. A.W. Aller, L.A. Kraus, and M.-C. Bissery In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract 1923] Proc Am Assoc Cancer Res 41 2000 303
61. M.-C. Bissery, H. Bouchard, and J.F. Riou Preclinical evaluation of TXD258, a new taxoid [abstract 1364] Proc Am Assoc Cancer Res 41 2000 214
62. E.A. Singer, and R. Srinivasan Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events Urol Oncol 30 Suppl. 4 2012 S15 S19
63. ® (cabazitaxel) [package insert]. Bridgewater, NJ: Sanofi-Aventis, U.S. LLC, June 2010.
64. ® (abiraterone acetate) [package insert]. Horsham, PA: Centocor Ortho Biotech, Inc., April 2011.
65. ® (zoledronic acid) [package insert]. East Hanover, PA: Novartis Pharmaceuticals Corporation, June 2011.
66. F. Saad, D.M. Gleason, and R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostatic carcinoma J Natl Cancer Inst 94 2002 1458 1468
67. F. Dayyani, G.E. Gallick, and C.J. Logothetis Novel therapies for metastatic castrate-resistant prostate cancer J Natl Cancer Inst 103 2011 1665 1675
68. ® (denosumab) [package insert]. Thousand Oak, CA: Amgen, Inc., November 2010.
69. D.H. Henry, L. Costa, and F. Goldwasser Randomized, double-blind study of denosumab vs. zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 2011 1125 1132
70. A.T. Stopeck, A. Lipton, and J.J. Body Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 2010 5132 5139
71. R. Melzack The McGill Pain Questionnaire: major properties and scoring methods Pain 1 1975 277 299
72. A. Gater, L. Abetz-Webb, and C. Battersby Pain in castration-resistant prostate cancer with bone metastases: a qualitative study Health Qual Life Outcomes 9 2011 1 11
73. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singa 23 2 1994 129 138
74. J.T. Farrar, J.P. Young, and L. LaMoreaux Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale Pain 94 2001 149 158
75. P. Esper, F. Mo, and G. Chodak Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument Urology 50 1997 920 928
76. D.F. Cella, D.S. Tulsky, and G. Gray The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 1993 570 579
77. D. Cella, M.B. Nichol, and D. Eton Estimating clinically meaningful changes for the functional assessment of cancer therapy - prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer Value Health 12 2009 124 129
78. C.N. Sternberg, A. Molina, and S. North Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy Ann Oncol 4 2013 1017 1025